[go: up one dir, main page]

CA3262869A1 - Traitement d'une lésion organique aiguë à l'aide de cd39, de cd39 recombinant - Google Patents

Traitement d'une lésion organique aiguë à l'aide de cd39, de cd39 recombinant

Info

Publication number
CA3262869A1
CA3262869A1 CA3262869A CA3262869A CA3262869A1 CA 3262869 A1 CA3262869 A1 CA 3262869A1 CA 3262869 A CA3262869 A CA 3262869A CA 3262869 A CA3262869 A CA 3262869A CA 3262869 A1 CA3262869 A1 CA 3262869A1
Authority
CA
Canada
Prior art keywords
recombinant
treatment
organ injury
acute organ
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3262869A
Other languages
English (en)
Inventor
Claudio Calonder
Ghionul Ibram
Guido Junge
Matthew James Rowland
Max Philipp Taubert
Max Warncke
Hermann Markus Weiss
Yinong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3262869A1 publication Critical patent/CA3262869A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3262869A 2022-07-29 2023-07-27 Traitement d'une lésion organique aiguë à l'aide de cd39, de cd39 recombinant Pending CA3262869A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263369839P 2022-07-29 2022-07-29
PCT/IB2023/057612 WO2024023745A1 (fr) 2022-07-29 2023-07-27 Traitement d'une lésion organique aiguë à l'aide de cd39, de cd39 recombinant

Publications (1)

Publication Number Publication Date
CA3262869A1 true CA3262869A1 (fr) 2024-02-01

Family

ID=87570979

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3262869A Pending CA3262869A1 (fr) 2022-07-29 2023-07-27 Traitement d'une lésion organique aiguë à l'aide de cd39, de cd39 recombinant

Country Status (8)

Country Link
EP (1) EP4561608A1 (fr)
JP (1) JP2025524942A (fr)
KR (1) KR20250044705A (fr)
CN (1) CN119604301A (fr)
CA (1) CA3262869A1 (fr)
IL (1) IL318380A (fr)
TW (1) TWI891029B (fr)
WO (1) WO2024023745A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38299A (es) * 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos

Also Published As

Publication number Publication date
IL318380A (en) 2025-03-01
JP2025524942A (ja) 2025-08-01
TWI891029B (zh) 2025-07-21
CN119604301A (zh) 2025-03-11
WO2024023745A1 (fr) 2024-02-01
EP4561608A1 (fr) 2025-06-04
TW202404627A (zh) 2024-02-01
KR20250044705A (ko) 2025-04-01

Similar Documents

Publication Publication Date Title
IL308698A (en) Tissue treatment system
CA3254230A1 (fr) Traitement de la depression
IL315403A (en) Miramatinib treatment
CA226061S (en) Pet dental treat
IL318380A (en) Treatment of acute organ injury using CD39, recombinant CD39
CA223597S (en) Hydrotherapy apparatus, medical apparatus
GB202319954D0 (en) Treatment
GB202319658D0 (en) Treatment
GB202319443D0 (en) Treatment
GB202318845D0 (en) Treatment
CA227912S (en) Dental treat
GB202311007D0 (en) Treatment
GB202304853D0 (en) Treatment
GB202218460D0 (en) Treatment
GB202214206D0 (en) Treatment
GB202212125D0 (en) Treatment
GB202204288D0 (en) Treatment
GB202204070D0 (en) Treatment
GB202212566D0 (en) Combination treatment
GB202201069D0 (en) Treatment
GB202307730D0 (en) Wood treatment
CA218194S (en) Pet dental treat
CA3261181A1 (fr) Traitement de tissu
GB202313014D0 (en) Novel therapeutic treatment
GB202300605D0 (en) Tobacco treatment